<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5553966</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0211</article-id><article-id pub-id-type="publisher-id">ONCO12184</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>31</subject><subject>7</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>A Phase II Multi&#x02010;Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma</article-title></title-group><contrib-group><contrib id="onco12184-cr-0001" contrib-type="author" corresp="yes"><name><surname>Burotto</surname><given-names>Mauricio</given-names></name><address><email>mauricioburotto@yahoo.com</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12184-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12184-cr-0002" contrib-type="author"><name><surname>Edgerly</surname><given-names>Maureen</given-names></name><xref ref-type="aff" rid="onco12184-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12184-cr-0003" contrib-type="author"><name><surname>Velarde</surname><given-names>Margarita</given-names></name><xref ref-type="aff" rid="onco12184-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12184-cr-0004" contrib-type="author"><name><surname>Balasubramaniam</surname><given-names>Sanjeeve</given-names></name><xref ref-type="aff" rid="onco12184-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12184-cr-0005" contrib-type="author"><name><surname>Drabkin</surname><given-names>Harry</given-names></name><xref ref-type="aff" rid="onco12184-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12184-cr-0006" contrib-type="author"><name><surname>Gormaz</surname><given-names>Juan G.</given-names></name><xref ref-type="aff" rid="onco12184-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12184-cr-0007" contrib-type="author"><name><surname>O'Sullivan</surname><given-names>Ciara</given-names></name><xref ref-type="aff" rid="onco12184-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12184-cr-0008" contrib-type="author"><name><surname>Madan</surname><given-names>Ravi</given-names></name><xref ref-type="aff" rid="onco12184-aff-0002"><sup>b</sup></xref></contrib><contrib id="onco12184-cr-0009" contrib-type="author"><name><surname>Fojo</surname><given-names>Tito</given-names></name><xref ref-type="aff" rid="onco12184-aff-0006"><sup>f</sup></xref></contrib><aff id="onco12184-aff-0001"><label><sup>a</sup></label><institution>Cl&#x000ed;nica Alemana de Santiago</institution>, <city>Santiago</city>, <country country="CL">Chile</country>
</aff><aff id="onco12184-aff-0002"><label><sup>b</sup></label><institution>National Cancer Institute (NCI)</institution>, <city>Bethesda</city>, <state>Maryland</state>, <country country="US">USA</country>
</aff><aff id="onco12184-aff-0003"><label><sup>c</sup></label><institution>U.S. Food and Drug Administration</institution>, <city>Silver Spring</city>, <state>Maryland</state>, <country country="US">USA</country>
</aff><aff id="onco12184-aff-0004"><label><sup>d</sup></label><institution>Medical University of South Carolina</institution>, <city>Charleston</city>, <state>South Carolina</state>, <country country="US">USA</country>
</aff><aff id="onco12184-aff-0005"><label><sup>e</sup></label><institution>Mayo Clinic, Indianapolis</institution>, <state>Indiana</state>, <country country="US">USA</country>
</aff><aff id="onco12184-aff-0006"><label><sup>f</sup></label><institution>Columbia University</institution>, <city>New York</city>, <state>New York</state>, <country country="US">USA</country>
</aff></contrib-group><author-notes><fn id="onco12184-note-0001" fn-type="COI-statement"><p><italic>Disclosures of potential conflicts of interest may be found at the end of this article</italic>.</p></fn><corresp id="correspondenceTo"><label>*</label>Correspondence: Mauricio Burotto, M.D., Cl&#x000ed;nica Alemana de Santiago, Av Vitacura 5951, Santiago, Regi&#x000f3;n Metropolitana, Santiago, Chile 7650568. Telephone: 56&#x02010;9&#x02010;54240753; e&#x02010;mail: <email>mauricioburotto@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>7</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>8</issue><issue-id pub-id-type="doi">10.1002/onco.v22.8</issue-id><fpage>888</fpage><lpage>e84</lpage><history><date date-type="received"><day>29</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">&#x000a9; AlphaMedPress; the data published online to support this summary is the property of the authors</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12184.pdf"/><abstract><title>Abstract</title><sec id="onco12184-sec-0931"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12184-list-0002"><list-item id="onco12184-li-0200"><p>Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments.</p></list-item><list-item id="onco12184-li-0201"><p>The observation of three responses among the 30 patients with median progression&#x02010;free survival and overall survival of 8.3 and 15 months, respectively, indicates the combination has some activity, but it is not sufficient for further development.</p></list-item></list></p></sec><sec id="onco12184-sec-0232"><title>Background.</title><p>Treatment of metastatic renal cell carcinoma (mRCC) remains suboptimal. Preclinical data have previously shown that ixabepilone, a microtubule&#x02010;stabilizing agent approved for the treatment of breast cancer, is active in taxane&#x02010;sensitive and &#x02010;resistant cells. In this single&#x02010;arm phase II trial, we investigated a combination of ixabepilone plus bevacizumab in patients with refractory mRCC.</p></sec><sec id="onco12184-sec-0343"><title>Methods.</title><p>We enrolled 30 patients with histologically confirmed mRCC, clear cell subtype, who had not been previously treated with ixabepilone or bevacizumab but had received at least one prior U.S. Food and Drug Administration (FDA)&#x02010;approved treatment for renal cell carcinoma (RCC). The treatment regimen consisted of 6 mg/m<sup>2</sup> ixabepilone per day for 5 days and 15 mg/kg bevacizumab every 21 days. After 6 cycles, the treatment interval could be extended to every 28 days. The primary endpoint was the objective response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST). Secondary endpoints were progression&#x02010;free survival (PFS), overall survival (OS), and the toxicity of the combination.</p></sec><sec id="onco12184-sec-1034"><title>Results.</title><p>The median number of prior therapies was two (range per patient one to five). Patients received a median of 8 cycles of ixabepilone plus bevacizumab (range 2&#x02013;54). The median follow&#x02010;up was 36.4 months (range 23.5&#x02013;96.5). Nineteen patients (63.3%) had stable disease as a best response. Three patients (10%) had a partial response. The median PFS was 8.3 months (95% confidence interval [CI], 4.9&#x02013;10.6) and the median OS was 15.0 months (95% CI, 11.3&#x02013;28.8). The total number of cycle for safety evaluation was 289. Grade 3/4 adverse events (&#x0003e;5% incidence) included lymphopenia (16.7%), hypertension (6.7%), and leukopenia (6.7%).</p></sec><sec id="onco12184-sec-0335"><title>Conclusion.</title><p>The combination of ixabepilone and bevacizumab was well tolerated, with modest activity in second &#x02010; or later&#x02010;line mRCC, but it is not recommended as a therapy without further clinical development. Alternative combinations with these agents could be explored in future studies.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh">&#x07ecf;&#x09a8c;&#x0603b;&#x07ed3;</p><p xml:lang="zh">&#x02022; &#x05c3d;&#x07ba1;&#x05bf9;&#x05df2;&#x06709;&#x06cbb;&#x07597;&#x07684;&#x0957f;&#x0671f;&#x053cd;&#x05e94;&#x04e0d;&#x08db3;, &#x04f46;&#x080be;&#x07ec6;&#x080de;&#x0764c;&#x08bd5;&#x09a8c;&#x07684;&#x062db;&#x052df;&#x04ecd;&#x05177;&#x06709;&#x06311;&#x06218;&#x06027;&#x03002;</p><p xml:lang="zh">&#x02022; &#x05728;30&#x04f8b;&#x04e2d;&#x04f4d;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;&#x0671f;&#x0548c;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x05206;&#x0522b;&#x04e3a;8.3&#x04e2a;&#x06708;&#x0548c;15&#x04e2a;&#x06708;&#x07684;&#x060a3;&#x08005;&#x04e2d;&#x089c2;&#x05bdf;&#x05230;&#x04e09;&#x079cd;&#x07f13;&#x089e3;, &#x08868;&#x0660e;&#x08054;&#x05408;&#x06cbb;&#x07597;&#x05177;&#x06709;&#x090e8;&#x05206;&#x06548;&#x0679c;, &#x04f46;&#x04e0d;&#x08db3;&#x04ee5;&#x08fdb;&#x0884c;&#x08fdb;&#x04e00;&#x06b65;&#x05f00;&#x053d1;&#x03002;</p><p xml:lang="zh">&#x06458;&#x08981;</p><p xml:lang="zh"><bold><italic>&#x080cc;&#x0666f;</italic>.</bold>&#x08f6c;&#x079fb;&#x06027;&#x080be;&#x07ec6;&#x080de;&#x0764c;&#x0ff08;mRCC&#x0ff09;&#x07684;&#x06cbb;&#x07597;&#x06548;&#x0679c;&#x04e0d;&#x04f73;&#x03002;&#x065e2;&#x05f80;&#x04e34;&#x05e8a;&#x0524d;&#x06570;&#x0636e;&#x0663e;&#x0793a;, &#x04f0a;&#x06c99;&#x05339;&#x09686;&#x0ff08;&#x04e00;&#x079cd;&#x083b7;&#x06279;&#x07528;&#x04e8e;&#x06cbb;&#x07597;&#x04e73;&#x0817a;&#x0764c;&#x07684;&#x05fae;&#x07ba1;&#x07a33;&#x05b9a;&#x05242;&#x0ff09;&#x05728;&#x07d2b;&#x06749;&#x070f7;&#x0654f;&#x0611f;&#x0548c;&#x08010;&#x0836f;&#x06027;&#x07ec6;&#x080de;&#x04e2d;&#x05177;&#x06709;&#x06d3b;&#x06027;&#x03002;&#x05728;&#x0672c;&#x09879;&#x05355;&#x07ec4;&#x03001;II&#x0671f;&#x08bd5;&#x09a8c;&#x04e2d;, &#x05728;&#x096be;&#x06cbb;&#x06027;mRCC&#x060a3;&#x08005;&#x04e2d;&#x08003;&#x05bdf;&#x04e86;&#x08d1d;&#x04f10;&#x073e0;&#x05355;&#x06297;&#x08054;&#x05408;&#x04f0a;&#x06c99;&#x05339;&#x09686;&#x07684;&#x06cbb;&#x07597;&#x06548;&#x0679c;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x065b9;&#x06cd5;</italic>.</bold>&#x07814;&#x07a76;&#x05165;&#x07ec4;&#x04e86;30&#x04f8b;&#x07ecf;&#x07ec4;&#x07ec7;&#x05b66;&#x08bc1;&#x05b9e;&#x07684;mRCC&#x07684;&#x060a3;&#x08005;, &#x08fd9;&#x04e9b;&#x060a3;&#x08005;&#x05177;&#x06709;&#x0900f;&#x0660e;&#x07ec6;&#x080de;&#x04e9a;&#x0578b;, &#x06b64;&#x0524d;&#x0672a;&#x063a5;&#x053d7;&#x08fc7;&#x04f0a;&#x06c99;&#x05339;&#x09686;&#x06216;&#x08d1d;&#x04f10;&#x073e0;&#x05355;&#x06297;&#x06cbb;&#x07597;, &#x04f46;&#x081f3;&#x05c11;&#x063a5;&#x053d7;&#x08fc7;&#x04e00;&#x06b21;&#x07ecf;&#x07f8e;&#x056fd;&#x098df;&#x054c1;&#x0836f;&#x054c1;&#x076d1;&#x07763;&#x07ba1;&#x07406;&#x05c40;&#x0ff08;FDA&#x0ff09;&#x06279;&#x051c6;&#x07684;&#x080be;&#x07ec6;&#x080de;&#x0764c;&#x0ff08;RCC&#x0ff09;&#x0836f;&#x07269;&#x06cbb;&#x07597;&#x03002;&#x06cbb;&#x07597;&#x065b9;&#x06848;&#x04e3a;&#x0ff1a;&#x04f0a;&#x06c99;&#x05339;&#x09686;6 mg/m<sup>2</sup>/&#x05929;, &#x05171;5&#x05929;, &#x04ee5;&#x053ca;&#x06bcf;21&#x05929;&#x063a5;&#x053d7;&#x08d1d;&#x04f10;&#x073e0;&#x05355;&#x06297;15 mg/kg&#x03002;6&#x04e2a;&#x05468;&#x0671f;&#x0540e;, &#x06cbb;&#x07597;&#x095f4;&#x09694;&#x053ef;&#x05ef6;&#x0957f;&#x081f3;&#x06bcf;28&#x05929;&#x04e00;&#x04e2a;&#x05468;&#x0671f;&#x03002;&#x04e3b;&#x08981;&#x07ec8;&#x070b9;&#x0662f;&#x06839;&#x0636e;&#x05b9e;&#x04f53;&#x07624;&#x07597;&#x06548;&#x08bc4;&#x04ef7;&#x06807;&#x051c6;&#x0ff08;RECIST&#x0ff09;&#x08bc4;&#x04f30;&#x07684;&#x05ba2;&#x089c2;&#x07f13;&#x089e3;&#x07387;&#x03002;&#x06b21;&#x08981;&#x07ec8;&#x070b9;&#x04e3a;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;PFS&#x0ff09;&#x03001;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;OS&#x0ff09;&#x0548c;&#x08054;&#x05408;&#x07528;&#x0836f;&#x07684;&#x06bd2;&#x06027;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x0679c;</italic>.</bold>&#x04e2d;&#x04f4d;&#x065e2;&#x05f80;&#x06cbb;&#x07597;&#x06570;&#x04e3a;2&#x0ff08;&#x06bcf;&#x0540d;&#x060a3;&#x08005;&#x07684;&#x08303;&#x056f4;&#x04e3a;1&#x02010;5&#x0ff09;&#x03002;&#x060a3;&#x08005;&#x063a5;&#x053d7;&#x04f0a;&#x06c99;&#x05339;&#x09686;&#x08054;&#x05408;&#x08d1d;&#x04f10;&#x073e0;&#x05355;&#x06297;&#x06cbb;&#x07597;&#x07684;&#x04e2d;&#x04f4d;&#x05468;&#x0671f;&#x06570;&#x04e3a;8&#x0ff08;&#x08303;&#x056f4;&#x04e3a;2&#x02010;54&#x0ff09;&#x03002;&#x04e2d;&#x04f4d;&#x0968f;&#x08bbf;&#x065f6;&#x095f4;&#x04e3a;36.4&#x04e2a;&#x06708;&#x0ff08;&#x08303;&#x056f4;&#x04e3a;23.5&#x02010;96.5&#x0ff09;&#x03002;19&#x0540d;&#x060a3;&#x08005;&#x0ff08;63.3&#x0ff05;&#x0ff09;&#x07684;&#x075be;&#x075c5;&#x07a33;&#x05b9a;&#x04e3a;&#x06700;&#x04f73;&#x07f13;&#x089e3;&#x03002;3&#x0540d;&#x060a3;&#x08005;&#x0ff08;10%&#x0ff09;&#x04e3a;&#x090e8;&#x05206;&#x07f13;&#x089e3;&#x03002;&#x04e2d;&#x04f4d;PFS&#x04e3a;8.3&#x04e2a;&#x06708; [95&#x0ff05;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff08;CI&#x0ff09;, 4.9&#x02010;10.6], &#x04e2d;&#x04f4d;OS&#x04e3a;15.0&#x04e2a;&#x06708;&#x0ff08;95&#x0ff05;CI, 11.3&#x02010;28.8&#x0ff09;&#x03002;&#x05b89;&#x05168;&#x06027;&#x08bc4;&#x04ef7;&#x07684;&#x0603b;&#x05468;&#x0671f;&#x06570;&#x04e3a;289&#x03002;3&#x07ea7;&#x06216;4&#x07ea7;&#x04e0d;&#x0826f;&#x04e8b;&#x04ef6;&#x0ff08;&#x053d1;&#x0751f;&#x07387;&#x0003e;5&#x0ff05;&#x0ff09;&#x05305;&#x062ec;&#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x075c7;&#x0ff08;16.7&#x0ff05;&#x0ff09;&#x03001;&#x09ad8;&#x08840;&#x0538b;&#x0ff08;6.7&#x0ff05;&#x0ff09;&#x0548c;&#x0767d;&#x07ec6;&#x080de;&#x051cf;&#x05c11;&#x075c7;&#x0ff08;6.7&#x0ff05;&#x0ff09;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x08bba;</italic>.</bold>&#x04f0a;&#x06c99;&#x05339;&#x09686;&#x04e0e;&#x08d1d;&#x04f10;&#x073e0;&#x05355;&#x06297;&#x08054;&#x05408;&#x07ed9;&#x0836f;&#x07684;&#x08010;&#x053d7;&#x06027;&#x0826f;&#x0597d;, &#x05728;&#x04e8c;&#x07ebf;&#x06216;&#x04e8c;&#x07ebf;&#x04ee5;&#x04e0a;&#x07684;mRCC&#x06cbb;&#x07597;&#x04e2d;&#x05177;&#x06709;&#x04e2d;&#x05ea6;&#x06548;&#x0679c;, &#x04f46;&#x05728;&#x0672a;&#x08fdb;&#x0884c;&#x08fdb;&#x04e00;&#x06b65;&#x04e34;&#x05e8a;&#x05f00;&#x053d1;&#x07684;&#x060c5;&#x051b5;&#x04e0b;, &#x04e0d;&#x063a8;&#x08350;&#x05c06;&#x05176;&#x04f5c;&#x04e3a;&#x06cbb;&#x07597;&#x065b9;&#x06848;&#x03002;&#x05728;&#x0672a;&#x06765;&#x07684;&#x07814;&#x07a76;&#x04e2d;&#x053ef;&#x04ee5;&#x063a2;&#x07d22;&#x04e0e;&#x08fd9;&#x04e9b;&#x0836f;&#x07269;&#x08054;&#x07528;&#x07684;&#x066ff;&#x04ee3;&#x065b9;&#x06848;&#x03002;</p></trans-abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec sec-type="discussion" id="onco12184-sec-0001"><title>Discussion</title><p>The unproven hypothesis that angiogenesis is a key step in the development and metastasis of solid tumors [<xref rid="onco12184-bib-0001" ref-type="ref">1</xref>], especially mRCC [<xref rid="onco12184-bib-0002" ref-type="ref">2</xref>], led to the development of a large number of agents whose putative target was the vascular endothelial growth factor (VEGF) pathway. Several of these agent were shown to have modest activity in the therapy of mRCC and this led to their approval by regulatory agencies. However, given their limited activity, their use in combinations has been extensively explored. We studied the combination of ixabepilone, a microtubule&#x02010;targeting epothilone [<xref rid="onco12184-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12184-bib-0004" ref-type="ref">4</xref>], with bevacizumab, a monoclonal antibody that binds VEGF.</p><p>Preclinical data from several in vivo models including breast, kidney, lung, and colon cancers demonstrated increased activity of ixabepilone in combination with bevacizumab, suggesting a synergistic effect in both antitumor and antiangiogenic activities and the absence of overlapping toxicities [<xref rid="onco12184-bib-0005" ref-type="ref">5</xref>]. More recently, randomized trials reported acceptable activities and toxicities of combined therapy in platinum/taxane&#x02010;resistant cervical&#x02010;uterine [<xref rid="onco12184-bib-0006" ref-type="ref">6</xref>] and locally recurrent or metastatic breast cancer [<xref rid="onco12184-bib-0007" ref-type="ref">7</xref>].
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><caption><p>Best percentage change from baseline for target lesions per patient.</p></caption><graphic xlink:href="onco12184-fig-0001.jpg" position="anchor" id="nlm-graphic-1" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text>
</p><p>This investigation was designed as a single&#x02010;arm phase II multi&#x02010;center trial with a primary aim of determining the objective response rate of ixabepilone plus bevacizumab using RECIST criteria in patients with relapsed or refractory mRCC. We also evaluated PFS, OS, and toxicities of the combined therapy. The observed activity of the combined therapy was less than originally expected, considering results in an earlier phase II study of ixabepilone in renal cancer that demonstrated an objective response rate of 13% [<xref rid="onco12184-bib-0008" ref-type="ref">16</xref>]. Regarding side effects, the tested combination was well tolerated without major side effects or deaths related to treatment.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12184-fig-0002.jpg" position="anchor" id="nlm-graphic-5" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p><p>Despite the low response rate of 11.3%, the median PFS of 8.3 month and OS of 15 months compare favorably with putative antiangiogenic agents approved for mRCC in second&#x02010;line treatment before 2015 [<xref rid="onco12184-bib-0009" ref-type="ref">8</xref>], [<xref rid="onco12184-bib-0010" ref-type="ref">9</xref>], [<xref rid="onco12184-bib-0011" ref-type="ref">10</xref>]. Furthermore, with a median number of two previous lines of treatment, a majority of patients were receiving this treatment in third line, making this combination potentially active in the third&#x02010;line setting. However, recent advances in immunotherapy for RCC restrict the potential scope of this combination.</p></sec><sec id="onco12184-sec-1101"><title>Trial Information</title><p><def-list id="onco12184-lp-0001"><def-item><term id="onco12184-li-0202">Disease</term><def id="onco12184-li-0203"><p>Renal cell carcinoma &#x02013; clear cell</p></def></def-item><def-item><term id="onco12184-li-0204">Stage of Disease/Treatment</term><def id="onco12184-li-0205"><p>Metastatic/Advanced</p></def></def-item><def-item><term id="onco12184-li-0206">Prior Therapy</term><def id="onco12184-li-0207"><p>1 prior regimen</p></def></def-item><def-item><term id="onco12184-li-0208">Type of Study &#x02013; 1</term><def id="onco12184-li-0209"><p>Phase II</p></def></def-item><def-item><term id="onco12184-li-0210">Type of Study &#x02013; 2</term><def id="onco12184-li-0211"><p>Single arm</p></def></def-item><def-item><term id="onco12184-li-0212">Primary Endpoint</term><def id="onco12184-li-0213"><p>Overall response rate</p></def></def-item><def-item><term id="onco12184-li-0214">Secondary Endpoint</term><def id="onco12184-li-0215"><p>Overall survival</p></def></def-item><def-item><term id="onco12184-li-0216">Secondary Endpoint</term><def id="onco12184-li-0217"><p>Progression&#x02010;free survival</p></def></def-item><def-item><term id="onco12184-li-0218">Secondary Endpoint</term><def id="onco12184-li-0219"><p>Toxicity</p></def></def-item><def-item><term id="onco12184-li-0220">Investigator's Analysis</term><def id="onco12184-li-0221"><p>Active but results overtaken by other developments</p></def></def-item></def-list></p></sec><sec id="onco12184-sec-1201"><title>Drug Information for Phase II Ixabepilone + Bevacizumab</title><p><def-list id="onco12184-lp-0002"><def-item><term id="onco12184-li-0222">Drug 1</term><def id="onco12184-li-0223"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12184-li-0224">Generic/Working name</term><def id="onco12184-li-0225"><p>Ixabepilone</p></def></def-item><def-item><term id="onco12184-li-0226">Trade name</term><def id="onco12184-li-0227"><p>Ixempra</p></def></def-item><def-item><term id="onco12184-li-0228">Company name</term><def id="onco12184-li-0229"><p>Bristol&#x02010;Myers Squibb</p></def></def-item><def-item><term id="onco12184-li-0230">Drug type</term><def id="onco12184-li-0231"><p>Microtubule inhibitor</p></def></def-item><def-item><term id="onco12184-li-0232">Drug class</term><def id="onco12184-li-0233"><p>Microtubule&#x02010;targeting agent</p></def></def-item><def-item><term id="onco12184-li-0234">Dose</term><def id="onco12184-li-0235"><p>6 milligrams (mg) per squared meter (m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12184-li-0236">Route</term><def id="onco12184-li-0237"><p>IV</p></def></def-item><def-item><term id="onco12184-li-0238">Drug 2</term><def id="onco12184-li-0239"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12184-li-0240">Generic/Working name</term><def id="onco12184-li-0241"><p>Bevacizumab</p></def></def-item><def-item><term id="onco12184-li-0242">Trade name</term><def id="onco12184-li-0243"><p>Avastin</p></def></def-item><def-item><term id="onco12184-li-0244">Company name</term><def id="onco12184-li-0245"><p>Genentech/Roche</p></def></def-item><def-item><term id="onco12184-li-0246">Drug type</term><def id="onco12184-li-0247"><p>Antibody</p></def></def-item><def-item><term id="onco12184-li-0248">Drug class</term><def id="onco12184-li-0249"><p>Angiogenesis &#x02010; VEGF</p></def></def-item><def-item><term id="onco12184-li-0250">Dose</term><def id="onco12184-li-0251"><p>15 milligrams (mg) per kilogram (kg)</p></def></def-item><def-item><term id="onco12184-li-0252">Route</term><def id="onco12184-li-0253"><p>IV</p></def></def-item></def-list>
</p></sec><sec id="onco12184-sec-1301"><title>Patient Characteristics for Phase II Ixabepilone + Bevacizumab</title><p><def-list id="onco12184-lp-0003"><def-item><term id="onco12184-li-0254">Number of patients, male</term><def id="onco12184-li-0255"><p>23</p></def></def-item><def-item><term id="onco12184-li-0256">Number of patients, female</term><def id="onco12184-li-0257"><p>7</p></def></def-item><def-item><term id="onco12184-li-0258">Stage</term><def id="onco12184-li-0259"><p>Metastatic or recurrent</p></def></def-item><def-item><term id="onco12184-li-0260">Age</term><def id="onco12184-li-0261"><p>Median (range): 62.3 (44.3&#x02013;78.8)</p></def></def-item><def-item><term id="onco12184-li-0262">Number of prior systemic therapies</term><def id="onco12184-li-0263"><p>Median (range): 2 (1&#x02013;5)</p></def></def-item><def-item><term id="onco12184-li-0264">Performance Status: ECOG</term><def id="onco12184-li-0265"><p>0 &#x02014; 2</p><p>1 &#x02014; 24</p><p>2 &#x02014; 4</p><p>3 &#x02014;</p><p>unknown &#x02014;</p></def></def-item><def-item><term id="onco12184-li-0266">Cancer Types or Histologic Subtypes</term><def id="onco12184-li-0267"><p>Clear cell, 30</p></def></def-item></def-list></p></sec><sec id="onco12184-sec-1401"><title>Primary Assessment Method for Phase II Ixabepilone + Bevacizumab</title><p><def-list id="onco12184-lp-0004"><def-item><term id="onco12184-li-0268">Assessment</term><def id="onco12184-li-0269"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12184-li-0270">Number of patients screened</term><def id="onco12184-li-0271"><p>40</p></def></def-item><def-item><term id="onco12184-li-0272">Number of patients enrolled</term><def id="onco12184-li-0273"><p>30</p></def></def-item><def-item><term id="onco12184-li-0274">Number of patients evaluable for toxicity</term><def id="onco12184-li-0275"><p>30</p></def></def-item><def-item><term id="onco12184-li-0276">Number of patients evaluated for efficacy</term><def id="onco12184-li-0277"><p>30</p></def></def-item><def-item><term id="onco12184-li-0278">Evaluation method</term><def id="onco12184-li-0279"><p>RECIST 1.1</p></def></def-item><def-item><term id="onco12184-li-0280">Response assessment CR</term><def id="onco12184-li-0281"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12184-li-0282">Response assessment PR</term><def id="onco12184-li-0283"><p><italic>n</italic>&#x02009;=&#x02009;3 (10%)</p></def></def-item><def-item><term id="onco12184-li-0284">Response assessment SD</term><def id="onco12184-li-0285"><p><italic>n</italic>&#x02009;=&#x02009;19 (63.3%)</p></def></def-item><def-item><term id="onco12184-li-0286">Response assessment PD</term><def id="onco12184-li-0287"><p><italic>n</italic>&#x02009;=&#x02009;8 (26.7%)</p></def></def-item><def-item><term id="onco12184-li-0288">Response assessment OTHER</term><def id="onco12184-li-0289"><p><italic>n</italic>&#x02009;=&#x02009;0 (0%)</p></def></def-item><def-item><term id="onco12184-li-0290">(Median) duration assessments PFS</term><def id="onco12184-li-0291"><p>8.3 months, CI: 4.9&#x02013;10.6</p></def></def-item><def-item><term id="onco12184-li-0292">(Median) duration assessments OS</term><def id="onco12184-li-0293"><p>15.0 months, CI: 11.3&#x02013;29.8</p></def></def-item><def-item><term id="onco12184-li-0294">Kaplan&#x02010;Meier Time units</term><def id="onco12184-li-0295"><p>Months</p></def></def-item></def-list>
</p></sec><sec id="onco12184-sec-7441"><p>
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><caption><p>Best percentage change from baseline for target lesions per patient.</p></caption><graphic xlink:href="onco12184-fig-0005.jpg" position="anchor" id="nlm-graphic-9" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12184-sec-1402"><title>Secondary Assessment Method for Phase II Ixabepilone + Bevacizumab (PFS)</title><p><def-list id="onco12184-lp-0005"><def-item><term id="onco12184-li-0296">Assessment</term><def id="onco12184-li-0297"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12184-li-0298">Number of patients evaluated for efficacy</term><def id="onco12184-li-0299"><p>30</p></def></def-item><def-item><term id="onco12184-li-0300">Kaplan&#x02010;Meier Time units</term><def id="onco12184-li-0301"><p>months</p></def></def-item></def-list>
</p></sec><sec id="onco12184-sec-1501"><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12184-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12184-sec-7641"><p>
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12184-fig-0003.jpg" position="anchor" id="nlm-graphic-15" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12184-sec-1002"><title>Secondary Assessment Method for Phase II Ixabepilone + Bevacizumab (OS)</title><p><def-list id="onco12184-lp-0006"><def-item><term id="onco12184-li-0302">Assessment</term><def id="onco12184-li-0303"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12184-li-0304">Number of patients evaluated for efficacy</term><def id="onco12184-li-0305"><p>30</p></def></def-item><def-item><term id="onco12184-li-0306">Kaplan&#x02010;Meier Time units</term><def id="onco12184-li-0307"><p>months</p></def></def-item></def-list></p></sec><sec id="onco12184-sec-1723"><p>
<table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-19" specific-use="sourcefile-name" xlink:href="onco12184-tbl-0002"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12184-sec-8641"><p>
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="onco12184-fig-0004.jpg" position="anchor" id="nlm-graphic-21" specific-use="sourcefile-name" orientation="portrait"><alt-text>image</alt-text></graphic></boxed-text></p></sec><sec id="onco12184-sec-1801"><title>Adverse Events: Phase II Ixabepilone + Bevacizumab</title><p>
<table-wrap id="nlm-table-wrap-3" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-25" specific-use="sourcefile-name" xlink:href="onco12184-tbl-0003"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12184-note-0007"><p>Abbreviation: NC/NA, no change from baseline/no adverse event.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="onco12184-sec-2201"><title>Assessment, Analysis, and Discussion</title><p><def-list id="onco12184-lp-0007"><def-item><term id="onco12184-li-0308">Completion</term><def id="onco12184-li-0309"><p>Study completed</p></def></def-item><def-item><term id="onco12184-li-0310">Investigator's Assessment</term><def id="onco12184-li-0311"><p>Active but results overtaken by other developments</p></def></def-item></def-list>
</p></sec><sec id="onco12184-sec-2271"><p>Renal cell carcinoma is among the ten most frequently diagnosed cancers in the general population in the U.S. [<xref rid="onco12184-bib-0002" ref-type="ref">2</xref>], with approximately 63,000 new cases and almost 14,000 deaths from RCC each year [<xref rid="onco12184-bib-0012" ref-type="ref">12</xref>]. Given its refractory nature, mRCC remains a difficult problem with 5&#x02010;year survival rates of 8% [<xref rid="onco12184-bib-0002" ref-type="ref">2</xref>].</p><p>Interest in the angiogenesis hypothesis, especially its putative role in RCC led to the development of innumerable &#x0201c;antiangiogenic agents&#x0201d; that sought to interdict signaling through the VEGF pathway. Despite the approval of several similar agents for the treatment of mRCC by regulatory agencies, efficacy was modest and short&#x02010;lived, in part due to the emergence of resistance [<xref rid="onco12184-bib-0013" ref-type="ref">13</xref>]. This has provided the impetus to develop combination regimens using antiangiogenic agents in the hopes of improving therapeutic efficacy. For example, although initial studies with single&#x02010;agent bevacizumab in patients with mRCC demonstrated a significant increase in time to progression [<xref rid="onco12184-bib-0014" ref-type="ref">14</xref>], its efficacy was not consider sufficient for use as a single agent. It was then explored and subsequently approved by regulatory agencies for the treatment of mRCC in combination with interferon alfa, based on the results of a phase III trial [<xref rid="onco12184-bib-0015" ref-type="ref">15</xref>]. With this background, we embarked on a clinical trial exploring the activity of the combination of bevacizumab with ixabepilone. In preclinical studies, ixabepilone, a non&#x02010;taxane microtubule&#x02010;stabilizing agent, had been shown to be active against cancer cell lines intrinsically insensitive to taxanes as well as cell lines that had developed resistance. To date, the only regulatory approval for ixabepilone is in metastatic breast cancer as a monotherapy or in combination with capecitabine based on an open&#x02010;label phase III trial that enrolled 752 patients [<xref rid="onco12184-bib-0008" ref-type="ref">16</xref>].</p><p>In mRCC, we initially explored the activity of ixabepilone monotherapy in previously untreated patients [<xref rid="onco12184-bib-0008" ref-type="ref">16</xref>] using the same schedule of administration&#x02014;6 mg/m<sup>2</sup>/day, for 5 consecutive days every 3 weeks&#x02014;used in combination with bevacizumab in this trial. In the previous trial, the overall response rate was 13% with a median duration of response of 5.5 months and an OS of 19.25 months [<xref rid="onco12184-bib-0008" ref-type="ref">16</xref>]. This regimen is different from that approved in breast cancer (40 mg/m<sup>2</sup> every 3 weeks) and was chosen because of the lower rate of neurotoxicity. Another phase II trial with the 40 mg/m<sup>2</sup> every 3 weeks was published with 12 patients and no objective responses [<xref rid="onco12184-bib-0017" ref-type="ref">17</xref>]. Given that both ixabepilone and bevacizumab had demonstrated modest activity in mRCC, appeared not to have overlapping toxicities, and had shown encouraging activity in preclinical models, we chose to explore the combination of ixabepilone plus bevacizumab in mRCC. The results demonstrated the combination was well tolerated with modest activity.</p><p>In our view, the recent approval of cabozantinib [<xref rid="onco12184-bib-0018" ref-type="ref">18</xref>] and especially nivolumab [<xref rid="onco12184-bib-0019" ref-type="ref">19</xref>] for the therapy of mRCC in second line [<xref rid="onco12184-bib-0002" ref-type="ref">2</xref>] make the further development of the tested combination very difficult. Accrual for this trial that began in 2009 was challenging and would be even more challenging in 2017.</p></sec></body><back><fn-group><fn fn-type="other" id="onco12184-note-2351"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov Identifier</ext-link>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00923139">NCT00923130</ext-link></p><p><bold>Sponsor(s)</bold>: National Cancer Institute (NCI)</p><p><bold>Principal Investigator</bold>: Tito Fojo</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12184-note-4392"><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p></fn></fn-group><sec id="onco12184-sec-0002" sec-type="disclosure"><title>Disclosures</title><p>The authors indicated no financial relationships.</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12184-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12184-cit-0001">
<string-name><surname>Kerbel</surname>
<given-names>RS.</given-names></string-name>
<article-title>Tumor angiogenesis</article-title>. <source>N Engl J Med</source>
<year>2008</year>;<volume>358</volume>:<fpage>2039</fpage>&#x02013;<lpage>2049</lpage>.
<pub-id pub-id-type="pmid">18463380</pub-id></mixed-citation></ref><ref id="onco12184-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12184-cit-0002">
<string-name><surname>Choueiri</surname>
<given-names>TK</given-names></string-name>, 
<string-name><surname>Motzer</surname>
<given-names>RJ.</given-names></string-name>
<article-title>Systemic therapy for metastatic renal&#x02010;cell carcinoma</article-title>. <source>N Engl J Med.</source>
<year>2017</year>;<volume>376</volume>:<fpage>354</fpage>&#x02013;<lpage>366</lpage>.
<pub-id pub-id-type="pmid">28121507</pub-id></mixed-citation></ref><ref id="onco12184-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12184-cit-0003">
<string-name><surname>Dorff</surname>
<given-names>TB</given-names></string-name>, 
<string-name><surname>Gross</surname>
<given-names>ME.</given-names></string-name>
<article-title>The epothilones: New therapeutic agents for castration&#x02010;resistant prostate cancer</article-title>. <source>The Oncologist</source>
<year>2011</year>;<volume>16</volume>:<fpage>1349</fpage>&#x02013;<lpage>1358</lpage>.
<pub-id pub-id-type="pmid">21964003</pub-id></mixed-citation></ref><ref id="onco12184-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12184-cit-0004">
<string-name><surname>Burotto</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Edgerly</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Poruchynsky</surname>
<given-names>M</given-names></string-name> et al. <article-title>Phase II clinical trial of ixabepilone in metastatic cervical carcinoma</article-title>. <source>The Oncologist</source>
<year>2015</year>;<volume>20</volume>:<fpage>725</fpage>&#x02013;<lpage>726</lpage>.
<pub-id pub-id-type="pmid">26040622</pub-id></mixed-citation></ref><ref id="onco12184-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12184-cit-0005">
<string-name><surname>Lee</surname>
<given-names>FY</given-names></string-name>, 
<string-name><surname>Covello</surname>
<given-names>KL</given-names></string-name>, 
<string-name><surname>Castaneda</surname>
<given-names>S</given-names></string-name> et al. <article-title>Synergistic antitumor activity of ixabepilone (BMS&#x02010;247550) plus bevacizumab in multiple in vivo tumor models</article-title>. <source>Clin Cancer Res</source>
<year>2008</year>;<volume>14</volume>:<fpage>8123</fpage>&#x02013;<lpage>8131</lpage>.
<pub-id pub-id-type="pmid">19088027</pub-id></mixed-citation></ref><ref id="onco12184-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12184-cit-0006">
<string-name><surname>Roque</surname>
<given-names>DM</given-names></string-name>, 
<string-name><surname>Ratner</surname>
<given-names>ES</given-names></string-name>, 
<string-name><surname>Silasi</surname>
<given-names>DA</given-names></string-name> et al. <article-title>Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review</article-title>. <source>Gynecol Oncol</source>
<year>2015</year>;<volume>137</volume>:<fpage>392</fpage>&#x02013;<lpage>400</lpage>.
<pub-id pub-id-type="pmid">25792179</pub-id></mixed-citation></ref><ref id="onco12184-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12184-cit-0007">
<string-name><surname>Rugo</surname>
<given-names>HS</given-names></string-name>, 
<string-name><surname>Barry</surname>
<given-names>WT</given-names></string-name>, 
<string-name><surname>Moreno&#x02010;Aspitia</surname>
<given-names>A</given-names></string-name> et al. <article-title>Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin&#x02010;bound nab&#x02010;paclitaxel once per week or ixabepilone with bevacizumab as first&#x02010;line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance)</article-title>. <source>J Clin Oncol</source>
<year>2015</year>;<volume>33</volume>:<fpage>2361</fpage>&#x02013;<lpage>2369</lpage>.
<pub-id pub-id-type="pmid">26056183</pub-id></mixed-citation></ref><ref id="onco12184-bib-0009"><label>8</label><mixed-citation publication-type="journal" id="onco12184-cit-0009">
<string-name><surname>Huang</surname>
<given-names>H</given-names></string-name>, 
<string-name><surname>Menefee</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Edgerly</surname>
<given-names>M</given-names></string-name> et al. <article-title>A phase II clinical trial of ixabepilone (Ixempra; BMS&#x02010;247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin</article-title>
<source>Cancer Res</source>
<year>2010</year>;<volume>16</volume>:<fpage>1634</fpage>&#x02013;<lpage>1641</lpage>.
</mixed-citation></ref><ref id="onco12184-bib-0010"><label>9</label><mixed-citation publication-type="journal" id="onco12184-cit-0010">
<string-name><surname>Escudier</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Eisen</surname>
<given-names>T</given-names></string-name>, 
<string-name><surname>Stadler</surname>
<given-names>WM</given-names></string-name> et al. <article-title>Sorafenib in advanced clear&#x02010;cell renal&#x02010;cell carcinoma</article-title>. <source>N Engl J Med</source>
<year>2007</year>;<volume>356</volume>:<fpage>125</fpage>&#x02013;<lpage>134</lpage>.
<pub-id pub-id-type="pmid">17215530</pub-id></mixed-citation></ref><ref id="onco12184-bib-0011"><label>10</label><mixed-citation publication-type="journal" id="onco12184-cit-0011">
<string-name><surname>Motzer</surname>
<given-names>RJ</given-names></string-name>, 
<string-name><surname>Escudier</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Oudard</surname>
<given-names>S</given-names></string-name> et al. <article-title>Efficacy of everolimus in advanced renal cell carcinoma: A double&#x02010;blind, randomised, placebo&#x02010;controlled phase III trial</article-title>. <source>Lancet</source>
<year>2008</year>;<volume>372</volume>:<fpage>449</fpage>&#x02013;<lpage>456</lpage>.
<pub-id pub-id-type="pmid">18653228</pub-id></mixed-citation></ref><ref id="onco12184-bib-1011"><label>11</label><mixed-citation publication-type="journal" id="onco12184-cit-1011">
<string-name><surname>Rini</surname>
<given-names>BI</given-names></string-name>, 
<string-name><surname>Escudier</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Tomczak</surname>
<given-names>P</given-names></string-name> et al. <article-title>Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>378</volume>:<fpage>1931</fpage>&#x02013;<lpage>1939</lpage>.
<pub-id pub-id-type="pmid">22056247</pub-id></mixed-citation></ref><ref id="onco12184-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12184-cit-0012">
<string-name><surname>Siegel</surname>
<given-names>RL</given-names></string-name>, 
<string-name><surname>Miller</surname>
<given-names>KD</given-names></string-name>, 
<string-name><surname>Jemal</surname>
<given-names>A.</given-names></string-name>
<article-title>Cancer statistics, 2017</article-title>. <source>CA Cancer J Clin</source>
<year>2017</year>;<volume>67</volume>:<fpage>7</fpage>&#x02013;<lpage>30</lpage>.
<pub-id pub-id-type="pmid">28055103</pub-id></mixed-citation></ref><ref id="onco12184-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="onco12184-cit-0013">
<string-name><surname>Zarrabi</surname>
<given-names>K</given-names></string-name>, 
<string-name><surname>Fang</surname>
<given-names>C</given-names></string-name>, 
<string-name><surname>Wu</surname>
<given-names>S.</given-names></string-name>
<article-title>New treatment options for metastatic renal cell carcinoma with prior anti&#x02010;angiogenesis therapy</article-title>. <source>J Hematol Oncol</source>
<year>2017</year>;<volume>10</volume>:<fpage>38</fpage>.
<pub-id pub-id-type="pmid">28153029</pub-id></mixed-citation></ref><ref id="onco12184-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="onco12184-cit-0014">
<string-name><surname>Yang</surname>, <given-names>JC</given-names></string-name>, 
<string-name><surname>Haworth</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Sherry</surname>
<given-names>RM</given-names></string-name> et al. <article-title>A randomized trial of bevacizumab, an anti&#x02010;vascular endothelial growth factor antibody, for metastatic renal cancer</article-title>. <source>N Engl J Med</source>
<year>2003</year>;<volume>349</volume>:<fpage>427</fpage>&#x02013;<lpage>434</lpage>.
<pub-id pub-id-type="pmid">12890841</pub-id></mixed-citation></ref><ref id="onco12184-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="onco12184-cit-0015">
<string-name><surname>Escudier</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Pluzanska</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Koralewski</surname>
<given-names>P</given-names></string-name> et al. <article-title>Bevacizumab plus interferon alfa&#x02010;2a for treatment of metastatic renal cell carcinoma: A randomised, double&#x02010;blind phase III trial</article-title>. <source>Lancet</source>
<year>2007</year>;<volume>370</volume>:<fpage>2103</fpage>&#x02013;<lpage>2111</lpage>.
<pub-id pub-id-type="pmid">18156031</pub-id></mixed-citation></ref><ref id="onco12184-bib-0008"><label>16</label><mixed-citation publication-type="journal" id="onco12184-cit-0008">
<string-name><surname>Thomas</surname>
<given-names>ES</given-names></string-name>, 
<string-name><surname>Gomez</surname>
<given-names>HL</given-names></string-name>, 
<string-name><surname>Li</surname>
<given-names>RK</given-names></string-name> et al. <article-title>Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment</article-title>. <source>J Clin Oncol</source>
<year>2007</year>;<volume>25</volume>:<fpage>5210</fpage>&#x02013;<lpage>5217</lpage>.
<pub-id pub-id-type="pmid">17968020</pub-id></mixed-citation></ref><ref id="onco12184-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="onco12184-cit-0017">
<string-name><surname>Posadas</surname>
<given-names>EM</given-names></string-name>, 
<string-name><surname>Undevia</surname>
<given-names>S</given-names></string-name>, 
<string-name><surname>Manchen</surname>
<given-names>E</given-names></string-name> et al. <article-title>A phase II study of ixabepilone (BMS&#x02010;247550) in metastatic renal&#x02010;cell carcinoma</article-title>. <source>Cancer Biol Ther</source>
<year>2007</year>;<volume>6</volume>:<fpage>490</fpage>&#x02013;<lpage>493</lpage>.
<pub-id pub-id-type="pmid">17457044</pub-id></mixed-citation></ref><ref id="onco12184-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="onco12184-cit-0018">
<string-name><surname>Choueiri</surname>
<given-names>TK</given-names></string-name>, 
<string-name><surname>Escudier</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Powles</surname>
<given-names>T</given-names></string-name>. <article-title>Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open&#x02010;label, phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2016</year>;<volume>17</volume>:<fpage>917</fpage>&#x02013;<lpage>927</lpage>.
<pub-id pub-id-type="pmid">27279544</pub-id></mixed-citation></ref><ref id="onco12184-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="onco12184-cit-0019">
<string-name><surname>Motzer</surname>
<given-names>RJ</given-names></string-name>, 
<string-name><surname>Escudier</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>McDermott</surname>
<given-names>DF.</given-names></string-name>
<article-title>Nivolumab versus everolimus in advanced renal&#x02010;cell carcinoma</article-title>. <source>N Engl J Med</source>
<year>2015</year>;<volume>373</volume>:<fpage>1803</fpage>&#x02013;<lpage>1813</lpage>.
<pub-id pub-id-type="pmid">26406148</pub-id></mixed-citation></ref></ref-list></back></article>